Top

Breast Cancer Research

Published in:

01-12-2021 | Breast Cancer | Research article

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

Authors: Evelien Schaafsma, Baoyi Zhang, Merit Schaafsma, Chun-Yip Tong, Lanjing Zhang, Chao Cheng

Published in: Breast Cancer Research | Issue 1/2021

Abstract

Background

The Oncotype DX breast recurrence score has been introduced more than a decade ago to aid physicians in determining the need for systemic adjuvant chemotherapy in patients with early-stage, estrogen receptor (ER)+, lymph node-negative breast cancer.

Methods

In this study, we utilized data from The Surveillance, Epidemiology, and End Results (SEER) Program to investigate temporal trends in Oncotype DX usage among US breast cancer patients in the first decade after the introduction of the Oncotype DX assay.

Results

We found that the use of Oncotype DX has steadily increased in the first decade of use and that this increase is associated with a decreased usage of chemotherapy. Patients who utilized the Oncotype DX test tended to have improved survival compared to patients who did not use the assay even after adjusting for clinical variables associated with prognosis. In addition, chemotherapy usage in patients with high-risk scores is associated with significantly longer overall and breast cancer-specific survival compared to high-risk patients who did not receive chemotherapy. On the contrary, patients with low-risk scores who were treated with chemotherapy tended to have shorter overall survival compared to low-risk patients who forwent chemotherapy.

Conclusion

We have provided a comprehensive temporal overview of the use of Oncotype DX in breast cancer patients in the first decade after Oncotype DX was introduced. Our results suggest that the use of Oncotype DX is increasing in ER+ breast cancer and that the Oncotype DX test results provide valuable information for patient treatment and prognosis.

Available only for authorised users

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. https://doi.org/10.1002/ijc.29210.CrossRefPubMed

Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer. 2019;11:151–64.PubMedPubMedCentral

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. 2019;5:1–31.CrossRef

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. J Natl Cancer Inst. 2014;106(5). https://doi.org/10.1093/jnci/dju055.

Female Breast Cancer Subtypes - Cancer Stat Facts. SEER. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html

Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479–84. https://doi.org/10.1056/NEJM198902233200802.CrossRefPubMed

Fisher B, Jeong J-H, Bryant J, Anderson S, Dignam J, Fisher ER, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004;364(9437):858–68. https://doi.org/10.1016/S0140-6736(04)16981-X.CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet. 2012;379:432–44.CrossRef

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N Engl J Med. 2004;351(27):2817–26. https://doi.org/10.1056/NEJMoa041588.CrossRefPubMed

10.

Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8(3):R25. https://doi.org/10.1186/bcr1412.CrossRefPubMedPubMedCentral

11.

Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13(5):477–93. https://doi.org/10.1634/theoncologist.2007-0248.CrossRefPubMed

12.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312. https://doi.org/10.1200/JCO.2007.14.2364.CrossRefPubMed

13.

Ramsey SD, Barlow WE, Gonzalez-Angulo AM, Tunis S, Baker L, Crowley J, et al. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials. 2013;34(1):1–9. https://doi.org/10.1016/j.cct.2012.09.003.CrossRefPubMed

14.

National Comprehensive Cancer Network. NCCN guidelines, version 6. 2020;2020.

15.

Partin JF, Mamounas EP. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer. Ann Surg Oncol. 2011;18(12):3399–406. https://doi.org/10.1245/s10434-011-1698-z.CrossRefPubMed

16.

Ademuyiwa FO, Miller A, O’Connor T, Edge SB, Thorat MA, Sledge GW, et al. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat. 2011;126(3):797–802. https://doi.org/10.1007/s10549-010-1329-6.CrossRefPubMed

17.

Kapadia S, Gudiwada SP, Kaji AH, Chlebowski RT, Venegas R, Ozao-Choy J, et al. Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result? Breast J. 2020;26(11):2199–202.CrossRef

18.

Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, et al. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2020.

19.

Tzeng JP, Mayer D, Richman AR, Lipkus I, Han PK, Valle CG, et al. Women’s experiences with genomic testing for breast cancer recurrence risk. Cancer. 2010;116(8):1992–2000. https://doi.org/10.1002/cncr.24990.CrossRefPubMed

20.

Guth AA, Fineberg S, Fei K, Franco R, Bickell N. Utilization of Oncotype DX to predict chemotherapy use in an inner-city population. JCO Am Soc Clin Oncol. 2011;29:e11131.CrossRef

21.

Goodwin M, Hughes J, Diego M, Frazier T. Impact of OncoType DXTM Recurrence Score and Tumor Size on Making Chemotherapy Decisions in Breast Cancer Patients. Cancer Res. 2009;69:6039.

22.

Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23(29):7265–77. https://doi.org/10.1200/JCO.2005.02.0818.CrossRefPubMed

23.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379:111–21.CrossRef

24.

Roberts MC, Miller DP, Shak S, Petkov VI. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Cancer Res Treat. 2017;163(2):303–10. https://doi.org/10.1007/s10549-017-4162-3.CrossRefPubMed

25.

McVeigh TP, Hughes LM, Miller N, Sheehan M, Keane M, Sweeney KJ, et al. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer. 2014;50(16):2763–70. https://doi.org/10.1016/j.ejca.2014.08.002.CrossRefPubMedPubMedCentral

26.

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016;2(1):16017. https://doi.org/10.1038/npjbcancer.2016.17.CrossRefPubMedPubMedCentral

27.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov): Oncotype DX Database (2004-2015), National Cancer Institute, DCCPS, Surveillance Research Program. 2019.

28.

Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, et al. 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer. 2012;118(3):788–96. https://doi.org/10.1002/cncr.26180.CrossRefPubMed

29.

Green N, Al-Allak A, Fowler C. Benefits of introduction of Oncotype DX® testing. Ann R Coll Surg Engl. 2019;101(1):55–9. https://doi.org/10.1308/rcsann.2018.0173.CrossRefPubMed

30.

Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;141(1):13–22. https://doi.org/10.1007/s10549-013-2666-z.CrossRefPubMedPubMedCentral

31.

Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, et al. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist. 2011;16(11):1520–6. https://doi.org/10.1634/theoncologist.2011-0045.CrossRefPubMedPubMedCentral

32.

Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26(25):4063–71. https://doi.org/10.1200/JCO.2007.14.4501.CrossRefPubMedPubMedCentral

33.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I-T, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65. https://doi.org/10.1016/S1470-2045(09)70314-6.CrossRefPubMed

34.

Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34. https://doi.org/10.1200/JCO.2009.24.4798.CrossRefPubMed

35.

Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol. 2009;99(6):319–23. https://doi.org/10.1002/jso.21244.CrossRefPubMed

36.

Lin C-Y, Mooney K, Choy W, Yang S-R, Barry-Holson K, Horst K, et al. Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions. Mod Pathol. 2018;31(4):562–8. https://doi.org/10.1038/modpathol.2017.172.CrossRefPubMed

37.

Rutter CE, Yao X, Mancini BR, Aminawung JA, Chagpar AB, Saglam O, et al. Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer. Clin Breast Cancer. 2016;16(1):59–62. https://doi.org/10.1016/j.clbc.2015.09.008.CrossRefPubMed

38.

Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg. 2008;196(4):527–9. https://doi.org/10.1016/j.amjsurg.2008.06.021.CrossRefPubMed

Title: Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
Authors: Evelien Schaafsma
Baoyi Zhang
Merit Schaafsma
Chun-Yip Tong
Lanjing Zhang
Chao Cheng
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Cytostatic Therapy
Published in: Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-021-01453-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer

Attenuated TGFB signalling in macrophages decreases susceptibility to DMBA-induced mammary cancer in mice

Adolescent and early adulthood inflammation-associated dietary patterns in relation to premenopausal mammographic density

STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment

Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992–2016

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1

Keynote webinar | Spotlight on antibody–drug conjugates in cancer